Le Lézard
Classified in: Health
Subject: SVY

In the report the venous stents market, the market is expected to reach US$ $ 1,727.4 Mn in 2025 from US$ 829.0 in 2017


NEW YORK, Dec. 13, 2018 /PRNewswire/ -- In the report the venous stents market, the market is expected to reach US$ $ 1,727.4 Mn in 2025 from US$ 829.0 in 2017. The market is estimated to grow with a CAGR of 9.7% from 2018-2025.

Read the full report: https://www.reportlinker.com/p05653787


The venous stents market is driven by the driving factor such as rising prevalence of venous diseases, technology advancement in stents technology and rising global geriatric population.The trend of development of advanced venous stents are likely to propel the growth of the market.

However, the factors such as stringent regulations for approval and high cost of surgical procedures are likely to restraint the market in the forecast period.
The venous stents market as per the technology the segment is segmented as wallstent technology, iliac vein stent technology. The market of iliac vein stent technology segment has the highest market share in 2017, contributing to venous stents market is of 73.9% and is expected to retain its dominance during the forecast period from 2018 to 2025. The development for the venous stents are done such that they are dedicated for the treatment of iliac venous obstruction are flexible, possess good radial force, MRI compatible, and are inexpensive. These technological advancements are enhancing accuracy, enabling additional capabilities to improve the workflow, and aiding in error reduction. Similarly, the wallstent technology segment contributed 26.1% of the market share in the year 2017 and is expected to be the fastest growing market in the coming forecast period.
The application segment of the venous stents market includes legs, chest, abdomen and arm. The application segment for the venous stents market was valued at US$ 36.82 Mn in 2017 and is estimated to reach US$ 63.39 Mn by 2025. The legs segments is likely to dominate the market in the coming future owing to the increasing incidences of the Deep Vein Thrombosis (DVT), growing geriatric population and increasing technological advancements to treat DVT are likely to enhance venous stents market. The chest segments are the fastest growing segment in the application and is expected to be the fastest growing segment in the forecast period owing to rising preference for minimally invasive procedures, rising incidences of chronic lung diseases, increasing prevalence of congenital diseases and growing obesity within the population are likely to propel the growth of the venous stents market.
Some of the major primary and secondary sources included in the report venous stents market are, World Health Organization, Center of Centers for Disease Control and Prevention (CDC), Venous Association of India (VAI), European Commission, Clinical Journal of American Society of Nephrology, NHS England, Allied Academies, Ministry of Health, Labour and Welfare and more.

Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the orthopedic braces and supports market.
-Highlights key business priorities in order to assist companies to realign their business strategies.
-The key findings and recommendations highlight crucial progressive industry trends in the global orthopedic braces and supports market, thereby allowing players across the value chain to develop effective long-term strategies.
-Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
-Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
-Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Read the full report: https://www.reportlinker.com/p05653787

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 10:10
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical...

at 10:10
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation...

at 10:07
The American Association of Critical-Care Nurses (AACN) has published "AACN Standards for Appropriate Staffing in Adult Critical Care," the specialty's first, action-oriented staffing standards. Appropriate staffing has long been one of the "AACN...

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...

at 10:05
Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I...

at 10:05
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held...



News published on and distributed by: